AUSTIN, Texas — September 10, 2026
EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental health disorders, severe and chronic pain and substance use disorders, supported by 34 provisional drug patent applications containing more than 2,700 pages of scientific and technical information. More than 20 filings are ketamine-based and more than five are based on dextromethorphan (DXM), while additional central nervous system programs remain undisclosed. The patent portfolio covers compositions, co-formulations, unit doses, kits, manufacturing methods, therapeutic uses, dosing regimens and immediate, delayed and extended-release profiles across multiple delivery formats. EPIK said the provisional filing strategy is intended to preserve development flexibility while establishing intellectual property around its emerging combination portfolio. The company expects to disclose additional details about the programs later in 2026 as it advances its drug development strategy.
Patent Strategy Covers Multiple CNS Indications
EPIK’s patent applications span a broad range of potential indications, including major depressive disorder and treatment-resistant depression, anxiety, post-traumatic stress disorder, severe and chronic pain, neuropathic pain, fibromyalgia, seizure disorders and substance use disorders. The filings also cover alcohol use disorder, cannabis use disorder and potential opioid-sparing or opioid-replacement approaches. EPIK is primarily developing sublingual oral formulations, topical formulations and parenteral co-formulations, including intravenous administration, while the broader portfolio encompasses oral lozenges, films, wafers, liquids, intranasal products and rectal suppositories. The company said most delivery approaches are designed for home use rather than clinic or hospital administration, potentially supporting more convenient treatment models. EPIK is working with Casimir Jones, S.C. on intellectual property strategy and prosecution, with the portfolio designed to protect combinations involving already FDA-approved active ingredients and differentiated formulations and delivery systems.
EPIK Advances Preclinical and Regulatory Development
The company has completed pharmacokinetic studies on lead formulations and initiated toxicology studies in rats, with full toxicology results expected before the end of 2026. EPIK said the active ingredients incorporated into its medicines are already FDA-approved compounds and are not Schedule I controlled substances. Based on this development strategy, the company intends to pursue a 505(b)(2) regulatory pathway for its synergistic combination medicines. EPIK plans to hold a pre-IND meeting with the U.S. Food and Drug Administration no later than February 2027, providing an important regulatory milestone as the company moves from formulation and preclinical development toward clinical planning. The extensive provisional patent activity, combined with completed pharmacokinetic work and ongoing toxicology, indicates that EPIK is building the development and intellectual-property foundation needed before revealing specific lead combinations and their intended clinical pathways.
Advertisement
EPIK Targets Mental Health, Pain and Addiction Markets
EPIK Biosciences is positioning its proprietary combination platform around unmet needs in mental health, pain management and addiction, with a focus on NMDA receptor modulation and potentially lower-side-effect treatment approaches. The company believes combining established compounds in proprietary formulations could create differentiated therapeutic profiles while supporting convenient administration outside traditional healthcare settings. EPIK expects to publicly disclose its full combination portfolio by the end of 2026, although the company noted that timing is not certain. The portfolio expansion also establishes potential opportunities across depression, anxiety, chronic pain and substance use disorders, areas where treatment accessibility, tolerability and dependence risks remain important development considerations. With 34 provisional patent applications, more than 2,700 pages of technical data, ongoing toxicology and a planned FDA pre-IND interaction, EPIK Biosciences is building an intellectual-property and regulatory foundation for a broad combination-medicine pipeline while preparing to reveal its lead programs later this year.
Source: EPIK Biosciences press release
